A citation-based method for searching scientific literature

Mark J O'Connor. Mol Cell 2015
Times Cited: 716







List of co-cited articles
577 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The DNA-damage response in human biology and disease.
Stephen P Jackson, Jiri Bartek. Nature 2009
15

The DNA damage response: making it safe to play with knives.
Alberto Ciccia, Stephen J Elledge. Mol Cell 2010
11

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
10

ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.
Andrew N Blackford, Stephen P Jackson. Mol Cell 2017
764
9

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
9

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
805
9

State-of-the-art strategies for targeting the DNA damage response in cancer.
Patrick G Pilié, Chad Tang, Gordon B Mills, Timothy A Yap. Nat Rev Clin Oncol 2019
385
9

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Jessica S Brown, Brent O'Carrigan, Stephen P Jackson, Timothy A Yap. Cancer Discov 2017
307
8

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Jacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, Paul W G Wijnhoven, Valeria Follia, Neil James, Paul M Farrington, Ankur Karmokar, Sophie E Willis, Jonathan Cairns,[...]. Nat Commun 2019
90
8

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
8

Non-homologous DNA end joining and alternative pathways to double-strand break repair.
Howard H Y Chang, Nicholas R Pannunzio, Noritaka Adachi, Michael R Lieber. Nat Rev Mol Cell Biol 2017
662
7

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
7

Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints.
Aziz Sancar, Laura A Lindsey-Boltz, Keziban Unsal-Kaçmaz, Stuart Linn. Annu Rev Biochem 2004
7

DNA damage sensing by the ATM and ATR kinases.
Alexandre Maréchal, Lee Zou. Cold Spring Harb Perspect Biol 2013
707
6

Mechanisms of DNA damage, repair, and mutagenesis.
Nimrat Chatterjee, Graham C Walker. Environ Mol Mutagen 2017
468
6

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
6

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
6

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
6

Biomarkers for Homologous Recombination Deficiency in Cancer.
Michal M Hoppe, Raghav Sundar, David S P Tan, Anand D Jeyasekharan. J Natl Cancer Inst 2018
124
6

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
6

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
772
6

The DNA damage response and cancer therapy.
Christopher J Lord, Alan Ashworth. Nature 2012
999
5

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Frank T Zenke, Astrid Zimmermann, Christian Sirrenberg, Heike Dahmen, Vladimir Kirkin, Ulrich Pehl, Thomas Grombacher, Claudia Wilm, Thomas Fuchss, Christiane Amendt,[...]. Mol Cancer Ther 2020
38
13

DNA repair pathways as targets for cancer therapy.
Thomas Helleday, Eva Petermann, Cecilia Lundin, Ben Hodgson, Ricky A Sharma. Nat Rev Cancer 2008
5

The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor.
Frederick W Goldberg, M Raymond V Finlay, Attilla K T Ting, David Beattie, Gillian M Lamont, Charlene Fallan, Gail L Wrigley, Marianne Schimpl, Martin R Howard, Beth Williamson,[...]. J Med Chem 2020
23
21

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
5

ATM in DNA repair in cancer.
Mei Hua Jin, Do-Youn Oh. Pharmacol Ther 2019
70
7

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
Nuala McCabe, Nicholas C Turner, Christopher J Lord, Katarzyna Kluzek, Aneta Bialkowska, Sally Swift, Sabrina Giavara, Mark J O'Connor, Andrew N Tutt, Małgorzata Z Zdzienicka,[...]. Cancer Res 2006
877
5

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
5

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
564
5

DNA repair, genome stability and cancer: a historical perspective.
Penny A Jeggo, Laurence H Pearl, Antony M Carr. Nat Rev Cancer 2016
360
5

Repair Pathway Choices and Consequences at the Double-Strand Break.
Raphael Ceccaldi, Beatrice Rondinelli, Alan D D'Andrea. Trends Cell Biol 2016
727
5

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Hailong Sheng, Yan Huang, Yazhi Xiao, Zhenru Zhu, Mengying Shen, Peitao Zhou, Zeqin Guo, Jian Wang, Hui Wang, Wencong Dai,[...]. J Immunother Cancer 2020
48
10

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
425
5


Replication stress and cancer.
Hélène Gaillard, Tatiana García-Muse, Andrés Aguilera. Nat Rev Cancer 2015
471
4

The essential kinase ATR: ensuring faithful duplication of a challenging genome.
Joshua C Saldivar, David Cortez, Karlene A Cimprich. Nat Rev Mol Cell Biol 2017
337
4

DNA-PK: a dynamic enzyme in a versatile DSB repair pathway.
Anthony J Davis, Benjamin P C Chen, David J Chen. DNA Repair (Amst) 2014
211
4

ATM and ATR as therapeutic targets in cancer.
Anika Maria Weber, Anderson Joseph Ryan. Pharmacol Ther 2015
334
4

ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.
Shuhei Matsuoka, Bryan A Ballif, Agata Smogorzewska, E Robert McDonald, Kristen E Hurov, Ji Luo, Corey E Bakalarski, Zhenming Zhao, Nicole Solimini, Yaniv Lerenthal,[...]. Science 2007
4


Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
4

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
4

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Benjamin H Lok, Eric E Gardner, Valentina E Schneeberger, Andy Ni, Patrice Desmeules, Natasha Rekhtman, Elisa de Stanchina, Beverly A Teicher, Nadeem Riaz, Simon N Powell,[...]. Clin Cancer Res 2017
170
4

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Junko Murai, Ying Feng, Guoying K Yu, Yuanbin Ru, Sai-Wen Tang, Yuqiao Shen, Yves Pommier. Oncotarget 2016
153
4

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
Hiroshi Hirai, Yoshikazu Iwasawa, Megumu Okada, Tsuyoshi Arai, Toshihide Nishibata, Makiko Kobayashi, Toshifumi Kimura, Naoki Kaneko, Junko Ohtani, Kazunori Yamanaka,[...]. Mol Cancer Ther 2009
323
4


High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
658
4

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
547
4

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.